Severe congenital myasthenic syndrome associated with novel biallelic mutation of the CHRND gene.


Journal

Neuromuscular disorders : NMD
ISSN: 1873-2364
Titre abrégé: Neuromuscul Disord
Pays: England
ID NLM: 9111470

Informations de publication

Date de publication:
04 2020
Historique:
received: 16 06 2019
revised: 14 01 2020
accepted: 16 02 2020
pubmed: 4 5 2020
medline: 27 7 2021
entrez: 4 5 2020
Statut: ppublish

Résumé

Congenital myasthenic syndromes (CMS) are a group of inherited disorders caused by mutations in genes encoding proteins essential for neuromuscular transmission. CMS is characterized by fatigable muscle weakness with onset at birth or in early childhood; rarely, symptoms may present later. The most frequently involved proteins are choline acetyltransferase, the endplate species of acetylcholinesterase and the acetylcholine receptor subunits. Defects in the cholinergic receptor nicotinic delta subunit (CHRND) are a rare cause for CMS but they should be considered in patients with a severe, early onset disease, with respiratory distress. We describe two sisters, clinically and genetically diagnosed with CMS, carrying two heteroallelic variants in the CHRND gene: c.730C>T; p.(Arg244Cys) and c.1304T>C; p.(Leu435Pro). The first variant has already been described yet no clinical relevance has been proved; the second one, is a novel variant documented here for the first time. These two cases expand the clinical spectrum of CMS linked to CHRND mutations.

Identifiants

pubmed: 32360402
pii: S0960-8966(20)30038-9
doi: 10.1016/j.nmd.2020.02.012
pii:
doi:

Substances chimiques

CHRND protein, human 0
Receptors, Cholinergic 0

Types de publication

Case Reports

Langues

eng

Sous-ensembles de citation

IM

Pagination

336-339

Subventions

Organisme : Medical Research Council
ID : MR/M006824/1
Pays : United Kingdom

Informations de copyright

Crown Copyright © 2020. Published by Elsevier B.V. All rights reserved.

Auteurs

Carmen Bonanno (C)

Department of Clinical and Experimental Medicine, Unit of Neurology and Neuromuscular Diseases, University of Messina, Messina, Italy.

Carmelo Rodolico (C)

Department of Clinical and Experimental Medicine, Unit of Neurology and Neuromuscular Diseases, University of Messina, Messina, Italy. Electronic address: crodolico@unime.it.

Ana Töpf (A)

John Walton, Muscular Dystrophy Research Centre, Institute of Translational and Clinical Research, Newcastle University and Newcastle Hospitals, Newcastle upon Tyne, UK.

Francesca Maria Foti (FM)

Neonatology and Neonatal Intensive Care Unit, "Bianchi-Melacrino-Morelli" Hospital, Reggio Calabria, Italy.

Wei-Wei Liu (WW)

Neurosciences Group, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK.

David Beeson (D)

Neurosciences Group, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK.

Antonio Toscano (A)

Department of Clinical and Experimental Medicine, Unit of Neurology and Neuromuscular Diseases, University of Messina, Messina, Italy.

Hanns Lochmüller (H)

Department of Neuropediatrics and Muscle Disorders, Faculty of Medicine, Medical Center - University of Freiburg, Freiburg, Germany; Centro Nacional de Análisis Genómico (CNAG-CRG), Center for Genomic Regulation, Barcelona Institute of Science and Technology (BIST), Barcelona, Catalonia, Spain; Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, Canada; Department of Medicine, Division of Neurology, The Ottawa Hospital, Ottawa, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH